Vatech (KOSDAQ 043150) 2026 stock outlook for foreign investors. A qualitative deep dive into its 3D cone-beam CT, panoramic X-ray and intraoral scanner lineup, the analog-to-digital dentistry shift, AI-reading software and consumable recurring revenue, plus risks from dental capex cyclicality, currency swings and competition from Dentsply Sirona and Planmeca.
Teleflex (TFX) 2026 stock analysis: recurring single-use device revenue across catheters, vascular access, and UroLift, the planned separation of Urology, Acute Care and OEM, the BIOTRONIK vascular deal, UroLift's growth debate, and margins funding deleveraging.
Nordson (NDSN) 2026 stock analysis: the precision adhesive and coatings dispensing moat, the three-segment structure spanning electronics test and inspection and medical fluid components, why recurring consumables revenue cushions the cycle, NBS-driven M&A compounding, and the electronics-cycle and valuation risks.
Interojo (KOSDAQ 119610) stock outlook for 2026. A qualitative deep dive into its silicone hydrogel one-day and color contact lens ODM edge, the Clalen own-brand, export expansion into Japan, Europe and the Middle East, the capacity build cycle, and FX leverage for foreign investors.
Globus Medical (GMED) 2026 stock analysis: the ExcelsiusGPS razor-blade robotics model, NuVasive merger synergies versus sales-force disruption, trauma and orthopedics expansion, and heavyweight competition from Medtronic and Stryker.
Jeisys Medical (287410) 2026 stock outlook. A deep qualitative look at its RF and HIFU energy-based devices, the recurring consumable-tip revenue model, POTENZA export momentum, the three-way fight with Classys and Wontech, ownership and M&A risk, and the metrics that actually move this KOSDAQ aesthetic name.